Stocks › AXSM
Axsome Therapeutics AXSM
US equityMarket cap rank #1751
$129.36 −$6.32 (-4.66%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $129.36 0.00%
Open$133.92
Prev close$135.68
Day range$128.23 – $135.09
Volume811.8K
Market cap$6.80B
P/E (TTM)–
Dividend yield–
AXSM Stock News
Headlines matching Axsome Therapeutics or the AXSM ticker, most recent first.
- Deutsche Bank Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Cuts Target Price to $267 Negative
- Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Hold Rating, Maintains Target Price $251
- H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $290
- Truist Financial Initiates Axsome Therapeutics(AXSM.US) With Buy Rating, Announces Target Price $285
- H.C. Wainwright Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
- Piper Sandler Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $258
- RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $297
- BMO Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $310
- Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $316
- Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $306
- Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $316 Positive
- Jefferies Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $380
- A Quick Look at Today's Ratings for Axsome Therapeutics(AXSM.US), With a Forecast Between $251 to $315
- RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Cuts Target Price to $297 Negative
- Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Cuts Target Price to $306 Negative
No comments yet — be the first to weigh in on AXSM.
Sign in to join the discussion.